FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL						
OMB	3235					
Number:	028					
Expires:	November 30					
	d average					
burden h	ours per					
roopono						

(Print or Type Responses)										
1. Name and Address of Reporting Perso MATHER CHARLES E IV	2. Issuer Na Symbol Tonix Phar [TNXP]				Ü	rp.	X Director Officer (give title	applicable)		
(Last) (First) (Middle) C/O TONIX PHARMACEUTICAI HOLDING CORP, 509 MADISON AVE., SUITE 306	(Month/Day/	Year)	nsac	tion			below)			
NEW YORK, NY 10022	4. If Amendn Filed(Month/Da		e Or	iginal			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip)	Non-Dei	rivative Securities Acquired, Disposed of, or Beneficially Owned								
	2A. Deemed 3. 4. Securities Execution Date, if Transaction Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		D)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D)	Beneficial Ownership				
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	(Instr. 4)	
Common Stock 04/26/2013		С		25,000	A	\$ 0.4	175,569	D		
Reminder: Report on a separate line for eadirectly or indirectly.	ch class of securitie	s benefic	ially	owned						
			inf re	ormatio	n coi res	ntaine pond	nd to the collection and in this form are r unless the form dis control number.	ot	SEC 1474 (9-02)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	Transaction	3A. Deemed	4.		5. N	umber	Date Exerci	isable and	7. Title and	Amount	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transact	ion	of		Expiration Da	te	of Underlyi	ng	Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Deri	vative	(Month/Day/Y	Year)	Securities		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Secu	ırities			(Instr. 3 and	14)	(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Acq	uired						Owned	Security:	(Instr. 4)
	Security					(A)							Following	Direct (D)	
						Disp	osed of						Reported	or Indirect	
						(D)							Transaction(s)	` /	
						,	tr. 3, 4,						(Instr. 4)	(Instr. 4)	
						and	5)								
											Amount				
								Data	Expiration		or				
									Date	Title	Number				
								Exercisable	Date		of				
				Code	V	(A)	(D)				Shares				
Warrants	\$ 0.4	04/26/2013		С			25,000	12/04/2012	12/04/2013	Common Stock	25,000	\$0	85,000	D	

Reporting Owners

Depositing Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
MATHER CHARLES E IV C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVE., SUITE 306 NEW YORK, NY 10022	X						

Signatures

/s/ Charles Mather IV	04/29/2013
Signature of Reporting Person	Date

Explanation of Responses:

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.